LGM
SYRE icon

Logos Global Management’s Spyre Therapeutics SYRE Stock Holding History

Logos Global Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500,000
Closed -$11.6M – 54
2024
Q4 		$11.6M Buy
500,000
+300,000
+150% +$8.8M 1.36% 27
2024
Q3 		$5.88M Sell
200,000
-375,000
-65% -$10.4M 0.63% 36
2024
Q2 		$13.5M Buy
575,000
+325,000
+130% +$11M 1.09% 30
2024
Q1 		$9.48M Buy
250,000
+100,000
+67% +$2.9M 0.77% 33
2023
Q4 		$3.23M Sell
150,000
-60,000
-29% -$827K 0.3% 48
2023
Q3 		$2.57M Buy
210,000
+84,285
+67% +$1.11M 0.34% 48
2023
Q2 		$1.42M Buy
+125,715
New +$596K 0.19% 47

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Logos Global Management's SYRE Position: Q1 2025 in Review

Logos Global Management sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 500,000 shares — an estimated $11.6M sold.

Logos Global Management first reported a position in SYRE in Q2 2023 and held it in 7 quarters. The position peaked at $13.5M in Q2 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Logos Global Management reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Logos Global Management sold 500,000 Spyre Therapeutics shares in Q1 2025, an estimated $11.6M.
  • Logos Global Management first reported a position in Spyre Therapeutics in Q2 2023 and held it in 7 quarters.
  • Logos Global Management's Spyre Therapeutics position peaked at $13.5M in Q2 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.